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expression of the dystrophin-glycoprotein complex in affected muscle. Therefore, these new rabbit 
monoclonal antibodies are suitable reagents for alpha-dystroglycan core protein detection and will 
enhance dystroglycan-related studies. 
Disciplines 
Agriculture | Animal Experimentation and Research | Animal Sciences | Diseases 
Comments 
This article is published as Fortunato MJ, Ball CE, Hollinger K, Patel NB, Modi JN, Rajasekaran V, et al. 
(2014) Development of Rabbit Monoclonal Antibodies for Detection of Alpha-Dystroglycan in Normal and 
Dystrophic Tissue. PLoS ONE 9(5): e97567. doi: 10.1371/journal.pone.0097567. 
Authors 
Marisa J. Fortunato, Charlotte E. Ball, Katrin Hollinger, Niraj B. Patel, Jill N. Modi, Vedika Rajasekaran, Dan 
J. Nonneman, Jason W. Ross, Eileen J. Kennedy, Joshua T. Selsby, and Aaron M. Beedle 
This article is available at Iowa State University Digital Repository: https://lib.dr.iastate.edu/ans_pubs/691 
Development of Rabbit Monoclonal Antibodies for
Detection of Alpha-Dystroglycan in Normal and
Dystrophic Tissue
Marisa J. Fortunato1, Charlotte E. Ball2, Katrin Hollinger3, Niraj B. Patel2, Jill N. Modi2,
Vedika Rajasekaran2, Dan J. Nonneman4, Jason W. Ross3, Eileen J. Kennedy1, Joshua T. Selsby3,
Aaron M. Beedle1*
1Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, Georgia, United States of America, 2Center for Undergraduate Research,
University of Georgia, Athens, Georgia, United States of America, 3Department of Animal Science, Iowa State University, Ames, Iowa, United States of America, 4United
States Department of Agriculture Agricultural Research Service, United States Meat Animal Research Center, Clay Center, Nebraska, United States of America
Abstract
Alpha-dystroglycan requires a rare O-mannose glycan modification to form its binding epitope for extracellular matrix
proteins such as laminin. This functional glycan is disrupted in a cohort of muscular dystrophies, the secondary
dystroglycanopathies, and is abnormal in some metastatic cancers. The most commonly used reagent for detection of
alpha-dystroglycan is mouse monoclonal antibody IIH6, but it requires the functional O-mannose structure for recognition.
Therefore, the ability to detect alpha-dystroglycan protein in disease states where it lacks the full O-mannose glycan has
been limited. To overcome this hurdle, rabbit monoclonal antibodies against the alpha-dystroglycan C-terminus were
generated. The new antibodies, named 5–2, 29–5, and 45–3, detect alpha-dystroglycan from mouse, rat and pig skeletal
muscle by Western blot and immunofluorescence. In a mouse model of fukutin-deficient dystroglycanopathy, all antibodies
detected low molecular weight alpha-dystroglycan in disease samples demonstrating a loss of functional glycosylation.
Alternately, in a porcine model of Becker muscular dystrophy, relative abundance of alpha-dystroglycan was decreased,
consistent with a reduction in expression of the dystrophin-glycoprotein complex in affected muscle. Therefore, these new
rabbit monoclonal antibodies are suitable reagents for alpha-dystroglycan core protein detection and will enhance
dystroglycan-related studies.
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Introduction
Dystroglycan, a dystrophin-associated glycoprotein, was first
isolated from skeletal muscle membranes [1], [2]. Encoded by the
gene DAG1, dystroglycan is post-translationally cleaved to form
two separate proteins, alpha-dystroglycan (aDG) and beta-
dystroglycan (bDG), which remain in complex by noncovalent
interactions [3]. Dystroglycan has since been found to be
expressed in a wide variety of tissues where it plays a number of
roles, including involvement in muscle integrity, cell signaling, and
development [4], [5], [6]. In healthy skeletal muscle, dystroglycan
is located at the sarcolemma as a component of the dystrophin-
glycoprotein complex (DGC) [7]. It is through involvement in this
complex that dystroglycan forms a structural link between the
extracellular matrix and the muscle cell cytoskeleton. aDG is
located extracellularly and interacts at the muscle membrane with
bDG, a transmembrane protein. aDG provides a structural
connection between muscle fibers and the basement membrane by
binding to laminin and other extracellular proteins [4]. aDG
undergoes extensive post-translational glycosylation, including O-
mannose glycan structures that are rarely found on mammalian
proteins, but are required for functional binding to extracellular
matrix proteins [8], [9].
Disruption of dystroglycan is associated with muscle, brain, and
other tissue abnormalities. Secondary loss of a- and bDG protein
at the muscle membrane occurs in some disorders of the DGC,
such as Duchenne and Becker muscular dystrophies [10], [11].
Primary dystroglycanopathies caused by mutations in the DAG1
gene encoding a- and bDG have been reported in two patients,
affecting dystroglycan function by impairing glycosylation of aDG
or by presumed disruption of the aDG – bDG binding interface
[12], [13]. In addition, aberrant glycosylation and disruption of
the O-mannose glycan of aDG, due to mutations in glycan
processing genes, leads to the development of muscular dystro-
phies known as secondary dystroglycanopathies [14]. Dystrogly-
canopathies cause a range of mild to severe pathologies and
include diseases such as Fukuyama congenital muscular dystrophy,
Walker-Warburg syndrome, and muscle-eye-brain disease [15],
[16], [17]. To date, aDG O-mannose glycosylation disorders have
been linked to mutations in more than a dozen genes, including
FKTN (fukutin), establishing a prevalent family of autosomal
recessive muscular dystrophies [18]. aDG O-mannose glycosyla-
PLOS ONE | www.plosone.org 1 May 2014 | Volume 9 | Issue 5 | e97567
tion defects have also been observed directly in cancer tissues and
are associated with enhanced metastatic potential [19], [20], [21],
further emphasizing the urgent need for accurate detection of
aDG independent of its glycosylation status.
Currently, the standard reagents used for detection of aDG are
IIH6 or VIA4–1. These reagents are mouse monoclonal
antibodies that require the functional O-mannose epitope for
aDG detection. In dystroglycanopathy disease states, however,
these antibodies are unable to detect the glycosylation-deficient
aDG. The study of aDG in disease has been restricted by access
and supply of limited polyclonal reagents against the aDG core
protein (e.g. Gt20adg, [2]). Therefore, it is important to develop a
reagent that has the ability to detect aDG regardless of
glycosylation state and that offers a potentially limitless supply.
To meet this need, a rabbit monoclonal antibody against the C-
terminal core protein of mouse aDG (aDGct) was generated. The
C-terminal core was selected as an ideal antigen because it has the
least post-translational processing and was predicted to be free of
challenges created by steric hindrance. The rabbit host was
selected in an effort to reduce the chance of nonspecific detection
in mouse tissue, as many dystroglycanopathies are modeled in
mice.
Three rabbit monoclonal antibodies against the core protein of
aDG – aDGct 5–2, 29–5, and 45–3– were generated and tested.
The ability to specifically detect aDG in mouse, rat, and pig tissue
as well as in two models of muscular dystrophy is demonstrated. In
addition, these antibodies are capable of detecting both normal
and glycosylation-deficient protein species, providing valuable
tools for investigating aDG in disease states.
Materials and Methods
Ethics Statement
Mice and rats were housed and tissues were collected in
accordance with the recommendations of the Guide for the Care
and Use of Laboratory Animals; all protocols were approved by
the University of Georgia Institutional Animal Care and Use
Committee (animal use protocols #A2010 08–153 and #A2013
07–016). All pig procedures were reviewed and approved by the
U.S. Meat Animal Research Center Animal Care and Use
Committee. All procedures complied with the Guide for the Care
and Use of Agricultural Animals in Agricultural Research and
Teaching [23]. All efforts were made to minimize animal suffering.
Animals
The tamoxifen-inducible Fktn dystroglycanopathy mouse model
has been described previously [22]. Briefly, Cre excision of Fktn
exon 2 was initiated via two doses of tamoxifen in healthy
littermate control (LC) and tamoxifen-inducible knockout (KO)
mice by oral gavage. Mice were euthanized by cervical dislocation
2.5 weeks post-tamoxifen and hind limb skeletal muscle was
dissected and frozen in liquid nitrogen for biochemical analyses.
Alternately, mouse hearts and brains for biochemistry were
dissected from a vehicle treated, healthy littermate control and a
tamoxifen-treated KO mouse at 21 weeks old (15 weeks post-
tamoxifen); brains were flash frozen in liquid nitrogen and hearts
were frozen in liquid nitrogen-cooled 2-methylbutane (Sigma). For
immunofluorescence, LC and inducible KO Tam-cre/Fktn mice
were dosed with tamoxifen twice at 6 weeks old and another two
times at almost 16 weeks old. Calf muscles were dissected from the
mice at 18 weeks old, covered in cryomatrix (ThermoFisher), and
frozen in liquid nitrogen-cooled 2-methylbutane (Sigma) for
cryosectioning.
Rat skeletal muscle, heart and brain were collected from a
young adult male Sprague-Dawley rat (Harlan, Dublin, VA).
Briefly, the rat was anesthetized with ketamine/xylazine by
intraperitoneal injection and underwent an unrelated surgery for
practice intrathecal injection. Following the surgery, the rat was
euthanized by cervical dislocation; quadriceps, heart and brain
Figure 1. Detection of aDG core protein from skeletal muscle of
normal and dystroglycanopathy mice. A) Western blot analysis of
aDG core protein detection by rabbit aDGct supernatants. Monoclonal
antibodies 5–2, 29–5, and 45–3 were tested on replicate Western blots
of solubilized murine skeletal muscle. Lane 1 contains normal murine
skeletal muscle (LC) and lane 2 contains skeletal muscle from a mouse
with a tamoxifen-induced fukutin-deficient dystroglycanopathy (KO).
Detection with antibody IIH6 shows glycosylated aDG for comparison.
Molecular weight standards are indicated in kDa. B) Wheat germ
agglutinin (WGA) purifications of LC and KO mouse brain and heart
lysates were conducted and the elution fraction was analyzed by
Western blot. Monoclonal antibody media supernatants 5–2, 29–5, and
45–3 were used to detect aDG core protein on replicate blots; detection
with IIH6 was performed by reprobing stripped blots. Molecular weight
standards are indicated in kDa.
doi:10.1371/journal.pone.0097567.g001
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were collected and frozen in liquid nitrogen for biochemistry;
tibialis anterior muscle was frozen for immunofluorescence as
above.
The Becker muscular dystrophy-affected pig has been described
previously [24], [25]. At the time of sacrifice (previously
described), skeletal muscle was taken from littermate and
dystrophin-insufficient BMD-affected pigs. Diaphragm muscle
was frozen for biochemistry and immunofluorescence as above
[24], [25].
Cloning
The sequence encoding the mouse aDG C-terminus (aDGct,
mouse amino acids 484–651; Uniprot #Q62165) was amplified
from C57BL/6J skeletal muscle cDNA using primers (according to
GenBank Accession BC007150, nt 1774–2278, plus start codon,
stop codon and modifications for cloning) sense 59-GACAC-
CATGGGAGTGCCCCGTGGGGGAGAA-39 and antisense 59-
AAGAATTCAGCCCCGAGTGATGTTCTGAAG-39 by PCR
with Easy A high fidelity enzyme (Agilent, Santa Clara, CA). The
purified DNA fragment was inserted into pCR8 (Life Technolo-
gies, Grand Island, NY), confirmed by sequencing, then inserted
into vector pET29a (EMD-Millipore, Billerica, MA) using NcoI
and EcoRI (New England BioLabs, Ipswich, MA). Proper
orientation of insertion was confirmed by restriction enzyme
digestion and additional Sanger sequencing (Georgia Genomics
Facility, Athens, GA).
Recombinant protein purification and concentration
aDGct-pET29a was transformed into BL21-Gold(DE3) com-
petent E. coli (Agilent) and the overnight express autoinduction
system 1 (EMD-Millipore) was used to induce protein expression
in the presence of 100 mg/ml kanamycin. Bacterial pellets were
resuspended in PBS/protease inhibitor buffer (protease inhibitor
cocktail: pepstatin A 0.6 mg/ml, aprotinin 0.5 mg/ml, leupeptin
0.5 mg/ml, calpain I inhibitor 2 mM, calpeptin 2 mM, PMSF
0.1 mM, benzamidine 0.75 mM) and were lysed by French cell
press. Samples were solubilized in triton X-100 (Fc = 1%) for
20 min at 4uC before centrifugation at 12,0006g for 10 min.
Triton-insoluble pellets were disrupted by sonication in 4 M urea
sonication buffer (50 mM Tris pH 7.4, 4 M urea, 0.6 mg pepstatin
A, 2 mM calpain I inhibitor, 2 mM calpeptin). Sonicated samples
were spun at 40006g and the resultant supernatants collected.
aDGct sonicated urea supernatants were precleared on DEAE
ion exchange resin and resulting DEAE void fractions were mixed
with NaCl to reach a final concentration of 100 mM. aDGct
samples were then run over S-protein agarose for S-tag protein
purification according to the manufacturer’s instructions (EMD-
Millipore). Protein was eluted from the column in two phases using
a total of 3 bed volumes of 0.2 M citrate. Eluent was neutralized
by the addition of 1 M Tris pH 8 at 1:10 dilution and 10 N NaOH
at 1:33 dilution.
Citrate elution fractions were pre-cleared by filtering through
50 kDa cut off spin filters (EMD-Millipore) to remove higher
molecular weight background proteins co-purifying with S-tag
aDGct. aDGct in the flow through was then buffer exchanged to
TBS-G (150 mM NaCl, 50 mM Tris pH 7.4, 1% glycerol) using
three rounds of dilution before a final concentration to .1.2 mg/
ml using a 10 kDa cut off spin filter (EMD-Millipore).
Rabbit monoclonal antibody generation
S-tag aDGct antigen was sent to Epitomics, Inc. (Burlingame,
CA) for contract custom rabbit monoclonal antibody generation.
Two rabbits were immunized with S-tag aDGct recombinant
protein in a series of 5 injections using a protocol specifically
optimized for the generation of IgG antibodies. Serum from one
rabbit had a substantially higher titer by ELISA and detection of
endogenous aDG in skeletal muscle lysates; this rabbit was selected
for splenectomy and hybridoma fusion according to Epitomics,
Inc. technology. Forty-one of 51 multi-clone hybridoma superna-
tants met minimum requirements for S-tag aDGct antigen
detection by ELISA screening and were tested by Western blot
on WGA-enriched mouse skeletal muscle and by immunofluores-
cence on normal and tamoxifen-induced Fktn conditional knock-
out mice according to standard protocols [22]. Multiple clones
with the highest specificity and sensitivity were selected for
subcloning. Thirty-five subclones were obtained and tested for
detection of endogenous mouse aDG. Skeletal muscle lysates from
healthy littermates and Fktn knockout mice were used instead of
WGA-enriched samples to increase the speed and throughput of
antibody testing by Western blot. Immunofluorescence was
performed as described above. The best subclones were further
expanded for Epitomics, Inc. project completion.
Hybridoma culture
Hybridoma subclones obtained from Epitomics, Inc. were
cultured in Epitomics hybridoma growth media (RPMI1640,
Epitomics’ rabbit hybridoma supplement A, 55 mM 2-mercapto-
ethanol cell culture grade, fetal bovine serum) according to the
manufacturer’s instructions. Subclones 5–2, 29–5 and 45–3 were
expanded for cryopreservation and supernatant collection. Sub-
clone supernatants were produced in regular serum, low serum,
and serum-free conditions according to Epitomics, Inc. protocols.
All supernatants were sterile filtered and supplemented with
40 mM Tris pH 7.5 and 5 mM EDTA pH 8 to stabilize solutions
for long-term storage. Aliquots of fresh, frozen, and spin
concentrated supernatant fractions were tested for each aDGct
monoclonal antibody subclone.
SDS-PAGE and Western blotting
Four hundred micrograms of solubilized skeletal muscle
supernatant (in 50 mM Tris, 150 mM NaCl, 1% triton X-100,
protease inhibitor cocktail) from TAM-inducible Fktn mice,
induced knockout (KO) and littermate (LC), were separated on
a 3%–15% gradient large-format SDS-PAGE [22]. Four hundred
micrograms of skeletal muscle lysate from Fktn littermate (healthy)
mice was also used as a control for pig and human sample testing.
Solubilized skeletal muscle, heart and brain from a Sprague-
Dawley rat were prepared in the same manner using 500 mg of
solubilized tissue (at concentrations ranging from 6–15 mg/ml)
per lane on SDS-PAGE. In addition, total protein lysates of
healthy skeletal and cardiac muscle from adult humans were
purchased and loaded at 500 mg per lane (BioChain Institute Inc.,
Newark CA). Proteins were transferred to PVDF and blocked with
1% milk in Tris-buffered saline (50 mM Tris, 150 mM NaCl) plus
0.1% Tween-20. aDGct hybridoma supernatants were tested at a
dilution of 1:5 and detected with goat anti-rabbit HRP secondary
antibody at 1:3000 (Millipore) using the Fluorchem HD2
chemiluminescent imaging system (Protein Simple, Santa Clara
CA) with Super Signal West Pico or Dura substrate (Pierce,
Rockford, IL). Following aDGct antibody testing, human sample
membranes were stripped in mild stripping buffer (1.5% glycine,
0.1% SDS, 1% Tween-20, pH 2.2), rinsed, and reprobed with
mouse IgM glycosylated aDG-specific antibody IIH6 at 1:100 in
1% milk, low salt TBS-T and goat anti-mouse IgM HRP antibody
at 1:3000 (Millipore) [22]. For mouse and rat samples, replicate
fresh blots were incubated in antibody IIH6 as above. IIH6 was a
kind gift from Dr. Kevin Campbell (University of Iowa).
Novel Alpha-Dystroglycan Antibodies
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Skeletal muscle protein, 35 mg per lane, from healthy and
dystrophin-insufficient BMD-affected pigs was separated on a 4–
20% gradient polyacrylamide mini-gel (Lonza, Rockland, ME).
Following separation the protein was transferred to a nitrocellulose
membrane (Bio-Rad, Hercules, CA). Membranes were stained
with Ponceau S to verify equal loading and transfer. Membranes
were blocked with 5% milk in low salt Tris-buffered saline (75 mM
NaCl, 50 mM Tris) with 0.1% Tween 20 (low salt TBS-T).
Membranes were subsequently incubated with aDGct hybridoma
supernatants diluted 1:3 with 1% milk in low salt TBS–T at 4uC
for three days. A secondary donkey anti-rabbit IgG linked to
horseradish peroxidase was used at 1:2000 (GE, Buckinghamshire,
UK). ECL reagent (EMD-Millipore) was applied and chemilumi-
nescence was captured with film. Membranes were subsequently
stripped for 15 min with restore Western blot stripping buffer
(Pierce) and re-probed with 1:50 IIH6 C4 (Developmental Studies
Hybridoma Bank, Iowa City, IA) and 1:2000 sheep anti-mouse
IgM-HRP (GE).
Wheat germ agglutinin (WGA) enrichment was performed on
mouse brain and heart lysates, human skeletal muscle and heart
lysates, and pig skeletal muscle lysates as described previously [22].
Briefly, mouse and pig tissues were homogenized in 50 mM Tris,
150 mM NaCl, 1% triton X-100, protease inhibitor cocktail and
solubilized by rotating at 4uC for 2 hr to overnight. Solubilized
supernatants were collected following a 142,0006g spin (or
21,0006g, mouse heart samples only) and protein concentration
was determined. Mouse and pig solubilized supernatants and
human skeletal muscle and heart lysates were incubated batch
method with WGA-agarose (Vector Laboratories, Burlingame CA)
overnight at 4uC using 500 mg (for all skeletal muscle and heart
samples) or 1 mg (brains only) of starting sample per SDS-PAGE
lane. WGA void fractions were collected, WGA agarose beads
were washed four times with WGA wash buffer (50 mM Tris,
150 mM NaCl, 0.1% triton X-100, protease inhibitors), and
WGA-bound proteins were eluted using 0.3 M N-acetylglucosa-
mine in WGA wash buffer.
Rabbit aDG encoding plasmid, DGFc5, with an Fc fusion tag
was a gift from Dr. Kevin Campbell (University of Iowa) [26].
HEK-293T cells were transfected with DGFc5 plasmid and cell
Figure 2. Immunofluorescent detection of aDG core protein on muscle sections of normal and dystroglycanopathy mice in the
presence and absence of the aDGct antigen. Calf muscle cryosections from a normal mouse (LC) and a tamoxifen-induced fukutin-deficient
dystroglycanopathy mouse (KO) were stained by aDG core monoclonal antibody media supernatants 5–2, 29–5, and 45–3, as well as IIH6, for
detection of aDG protein and functional glycan, respectively. Each antibody was pre-incubated with 18 mg of purified aDGct protein antigen or PBS
prior to staining. Asterisks mark matching fibers for comparison. Arrowheads mark neuromuscular junctions. 40X objective; 20 mm scale bar.
doi:10.1371/journal.pone.0097567.g002
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lysates with recombinant protein were collected and prepared for
SDS-PAGE according to standard protocols [27].
Immunofluorescence
Seven micron cryosections of mouse calf (gastrocnemius and
soleus) and rat tibialis anterior were mounted on slides. Tissues
were blocked with 5% donkey serum for 30 min at room
temperature and then incubated with 5–2, 29–5, or 45–3 aDGct
antibody at a dilution of 1:3 overnight at 4uC. For antigen
competition analysis, each monoclonal antibody media superna-
tant was pre-incubated with 18 mg of purified aDGct protein
antigen (50 mL) or 50 mL of PBS for 1.5 hr at 37uC with gentle
shaking. Then, 5% donkey serum (in PBS) was added to each pre-
mix, the samples were vortexed, cleared by centrifugation, and
added to the tissue slide (following the blocking step) for overnight
incubation at 4uC. Sections were washed with PBS and incubated
with anti-rabbit IgG secondary antibody coupled to Alexa Fluor
546 (1:500, Life Technologies); along with DAPI nuclear stain
(1:10,000). Slides were mounted using permafluor mountant
(ThermoFisher Scientific, Waltham, MA). Fluorescent imaging
was performed using an IX71 inverted fluorescent microscope
(Olympus, Center Valley, PA). All aDGct antibody images for a
particular species were taken under the same conditions. Indirect
immunofluorescence for glycosylated aDG using antibody IIH6
was performed as described previously [22]. Images were edited in
Photoshop (Adobe) for size, resolution, and intensity; all aDGct
images and controls were edited using identical settings.
Ten micron cryosections of pig diaphragm were washed in PBS
for 10 min and then blocked with 5% goat serum in PBS at room
temperature for 15 min. On each slide one section was incubated
overnight at 4uC with antibody 45–3 at a 1:3 dilution. The second
section was used as a negative control and incubated without a
primary antibody. The third section was used as a positive control
and was incubated with IIH6 at a dilution of 1:3. The next day,
sections were washed in PBS and incubated with secondary
antibody. For 45–3, anti-rabbit IgG (H+L) F(ab’)2 fragment
conjugated to Alexa Fluor 488 (Cell Signaling Technology,
Carlsbad, CA) was used at a dilution of 1:100. For IIH6, anti-
mouse fluorescein-conjugated (Millipore, Temecula, CA) was used
at a dilution of 1:100. Slides were mounted with slowfade gold
antifade reagent with DAPI (Invitrogen, Carlsbad, CA). All images
were taken under the same conditions.
Five micron sections of formalin fixed paraffin embedded
human diaphragm from a normal 26 year old male were
purchased (Biochain, Newark CA, Cat# T2234169, Lot
#B312032). Sections were treated to deparaffinized, retrieve
antigen and permeabilize for immunofluorescence as follows:
Xylene substitute, 265 min; 100% ethanol, 265 min; 95%
ethanol, 5 min; 80% ethanol, 5 min; 70% ethanol, 5 min; 50%
ethanol, 5 min; distilled H2O, 265 min; antigen retrieval solution
(10 mM sodium citrate, 0.05% Tween 20, pH 6.0), 30 min at
95uC, then 20 min cooling to room temperature; antigen retrieval
solution, 1 wash; rinse with running ddH2O, 5 min; 0.2% Triton-
X 100 in PBS, 10 min; PBS washes, 365 min; block in 5% donkey
serum in PBS, 30 min. Incubation with primary and secondary
antibodies, slide mounting and imaging were performed as
described for mouse and rat immunofluorescence (see above).
Image analyses and statistics
The intensity of each aDG protein band on Western blots of pig
skeletal muscle lysates was detected using Carestream Molecular
Imaging software (Carestream Health, Inc., Rochester, NY). All
measurements were adjusted for background signal. The aDG
band intensity of each healthy animal sample was averaged to
obtain the mean normal aDG intensity for each blot. The aDG
band intensity for each healthy and BMD-affected sample was
then divided by the average control aDG intensity from the same
blot to obtain a measure of the relative aDG quantity in each
sample, as detected by the respective antibody. These data were
plotted by scatter plot with mean and SEM using Prism 5
(GraphPad, La Jolla, CA). Total protein loaded per lane was
quantified from Ponceau S stained blots prior to Western blotting.
Protein loading from healthy versus BMD-affected pig samples
was not significantly different (two-tailed, unpaired T-test).
For immunofluorescent image quantification, 4 representative
images were collected from a section of each animal. Images were
converted to a binary format using the density slice function in
Openlab (PerkinElmer, Waltham, MA) and the total number of
positive pixels determined. Total positive pixels of the 4
representative images were summed for each animal and
Figure 3. Detection of aDG core protein in rat skeletal muscle,
heart, and brain tissue. Detection of rat aDG by aDGct antibody
supernatants was analyzed via Western blot and immunofluorescence.
A) Monoclonal antibodies 5–2, 29–5, and 45–3 were tested on replicate
Western blots of solubilized rat skeletal muscle (lane 1, SkM), rat heart
tissue (lane 2, H), and rat brain tissue (lane 3, B). Detection by IIH6 for
glycosylated aDG is shown for comparison. Molecular weight standards
are indicated in kDa. B) Immunofluorescent detection of aDG in rat
tibialis anterior muscle cryosections using antibodies 5–2, 29–5, and 45–
3. 20X objective; 100 mm scale bar.
doi:10.1371/journal.pone.0097567.g003
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normalized to the average of total positive pixels from control
samples. Data were plotted as described above.
Statistical calculations were performed using Prism 5 (Graph-
Pad). Each control versus affected sample pair for Western blot
band intensities and for immunofluorescent pixel intensities were
Figure 4. Detection of aDG core protein in a porcine model of Becker muscular dystrophy. A) Immunoblotting of healthy (N) and BMD-
affected (A) pig skeletal muscle homogenates was conducted with monoclonal antibodies 5–2, 29–5, and 45–3. IIH6 detection of glycosylated aDG
(reprobe) is shown. Molecular weight standards are indicated in kDa. B) Quantification of signal intensity of aDG detection by Western blot. aDG
bands were analyzed; the signal intensity for each sample was normalized to the average aDG expression of all controls on the same blot. The
resulting relative aDG expression is plotted for each individual control and BMD-affected sample (with group mean and SEM). C) Immunoblotting of
WGA-enriched protein eluted from 500 mg of skeletal muscle lysate from normal and BMD-affected pigs using monoclonal antibody media
supernatants 5–2, 29–5, 45–3, and IIH6 on replicate blots. Four hundred micrograms of skeletal muscle lysate (mSkM) from a normal mouse was run
along with the pig WGA elutions for comparison. D) Diaphragm muscle from healthy (normal) and BMD-affected pigs (BMD-affected) were stained
with 45–3 and IIH6. 20X objective; 100 mm scale bar. E) Quantification of pig aDG in normal and BMD-affected muscle by immunofluorescence. The
total number of aDG positive pixels summed from 4 representative images was normalized to the average of all normal images per antibody for each
control and BMD-affected sample. Asterisks indicate statistical significance between normal and affected pairs; * P = 0.01–0.05, ** P = 0.001–0.01, ***
P = 0.0001–0.001, **** P =,0.0001.
doi:10.1371/journal.pone.0097567.g004
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compared by a two-tailed, unpaired T-test. P-values are indicated
in figures as follows: *, P = 0.01–0.05, **, P = 0.001–0.01; ***,
P = 0.0001–0.001, ****, P=,0.0001.
Results
5–2, 29–5, and 45–3 detect aDG in murine skeletal
muscle from normal and fukutin-deficient
dystroglycanopathy mice
Rabbit monoclonal antibodies raised against aDG core protein
can detect the presence of aDG in skeletal muscle of both normal
and dystroglycanopathy mice. Dystroglycanopathies result in
abnormally glycosylated aDG, which separates as a lower
molecular weight band on SDS-PAGE. To evaluate the ability
of the new monoclonal antibodies to detect not only fully
glycosylated aDG, but also the smaller abnormal isoform, Western
blots were performed on solubilized mouse skeletal muscle lysates
from normal littermates and Fktn-deficient dystroglycanopathy
mice. aDGct antibodies 5–2, 29–5, and 45–3 were each able to
detect normal aDGwith similar efficacy at dilutions of 1:5 (Fig. 1A,
LC). The specificity of detection was verified by comparison to
blots of the same tissue sample labeled with IIH6 (Fig. 1A, far
right, LC). This antibody, which detects a glycan epitope of aDG,
labeled a broad band of 150 kDa, the same size as the
experimental antibodies in healthy mouse skeletal muscle.
Importantly, IIH6 detection was greatly reduced or absent in
Fktn-deficient skeletal muscle homogenates lacking glycosylated
aDG, however these bands are readily apparent in knockout
homogenates when exposed to all three aDGct experimental
antibodies (Fig. 1A, KO). 5–2, 29–5, and 45–3 each detected a
single aDG band at approximately 95 kDa in knockout muscle,
indicating reduced glycosylation compared to the unaffected
skeletal muscle sample (Fig. 1A, KO).
aDG undergoes tissue-specific glycosylation so its molecular
weight varies according to tissue type. To test the sensitivity of
aDGct monoclonal antibodies for other aDG species, each media
supernatant fraction was used for immunoblot of WGA-enriched
proteins from mouse heart and brain. 5–2, 29–5, and 45–3 each
detected a high molecular weight band in heart from a healthy
mouse that was also labelled by IIH6, confirming its identity as
aDG (Fig. 1B, LC). Similarly, all aDGct monoclonal antibodies
and IIH6 detected brain aDG at 100 kDa (Fig. 1B, LC). In
tamoxifen-treated inducible Fktn knockout heart, aDGct mono-
clonal antibodies detected a band near 95 kDa, consistent with
glycosylation-deficient aDG (Fig. 1B, KO). In the brain, 5–2, 29–
5, and 45–3 detected two bands, one matching normal aDG and
one, near 75 kDa, consistent with glycosylation-deficient aDG in
the brain (Fig. 1B, KO). The presence of both bands indicates that
tamoxifen-mediated Fktn excision was incomplete in the brain of
the induced knockout mouse.
In immunofluorescent staining of healthy mouse calf muscle
(Fig. 2), aDG could be detected by the aDGct 5–2, 29–5 and 45–3
antibodies. There was distinct sarcolemma staining and neuro-
muscular junctions were strongly labeled with each aDGct media
supernatant tested. Notably, pre-incubation of antibody with the
aDGct protein antigen blocked labelling, indicating that antibody
detection is specific for aDG. Glycosylation-specific staining of
aDG by IIH6 was similar to the aDGct core protein antibodies in
healthy muscle. IIH6 signal was not blocked by the aDGct protein
antigen as it targets a different (glycan) epitope. As expected for
Figure 5. Amino acid sequence alignment of the aDG C-terminus. The mouse aDG C-terminal antigen used for antibody generation is
aligned to rat, pig, human, and rabbit species-specific sequences using the Clustal 2.1 multiple sequence alignment tool [31]. The chicken aDG C-
terminus is also shown for comparison with a non-mammalian sequence. Amino acid numbering is according to the mouse sequence. Aligned
sequences are Uniprot No. Q62165 a.a. 484–651 (mouse), F1M8K0 a.a. 484–651 (rat), I3LD20 a.a. 469–635 (pig), Q14118 a.a. 486–653 (human), Q28685
a.a. 486–653 (rabbit), and A4VAR9 a.a. 487–654 (chicken). Amino acids are colored according to similar properties: red, small; blue, acidic; magenta,
basic; green, hydroxyl, sulfhydryl or amine. Consensus across all species aligned is indicated below each amino acid residue by symbols: asterisk,
conserved residue; colon, residues with strongly similar properties; period, residues with weakly similar properties; no symbol, no conservation of
properties. Each residue that is not identical to the corresponding mouse amino acid is highlighted in gray. Horizontal lines are used to group the
aDGct monoclonal antibody detection positive species (mouse, rat, pig) with the aDGct antibody detection negative species (human, rabbit fusion).
Asn524 (in bold) is the only residue that is conserved in all detection positive species and not in detection negative species.
doi:10.1371/journal.pone.0097567.g005
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core aDG detection, each antibody also stained the sarcolemma of
Fktn-deficient dystroglycanopathy mouse muscle (Fig. 2 KO).
There was some variation in signal intensity that was not strictly
correlated with the presence or absence of the aDG functional
glycan, shown by IIH6 (Fig. 2 KO). aDG core antibody 45–3
demonstrated the most consistent membrane staining in these
experiments. Overall, these data provide evidence of specific
recognition of endogenous mouse aDG by aDGct rabbit
monoclonal antibodies 5–2, 29–5 and 45–3.
In addition to regular hybridoma subclone media supernatants
(regular serum), low serum and serum-free supernatants, with or
without spin concentration, were also collected and tested on
solubilized murine skeletal muscle from both healthy and
dystroglycanopathy mice. All fractions successfully detected both
normal and glycosylation-deficient murine aDG by Western blot
and immunofluorescence (data not shown). For serum-free and
concentrated fractions, Western blot detection was effective at
dilutions ranging from 1:100–1:1000 (data not shown). Both
serum-free and serum-containing monoclonal antibody superna-
tants also retained aDG detection after one freeze/thaw cycle
without the addition of glycerol or other stabilizing agents. For
aDGct monoclonal antibody supernatants stored long-term at
4uC, a modest decrease in activity in some samples after 7–
8 months of storage has been noted (data not shown).
5–2, 29–5, and 45–3 detect aDG in skeletal muscle,
cardiac tissue, and brain tissue derived from normal
Sprague-Dawley rat
Following successful detection of aDG in mouse, similar
experiments were conducted to assess the ability of the experi-
mental aDGct antibodies to detect aDG in tissue derived from
rats. Each antibody was used to probe membranes containing
solubilized skeletal muscle, heart, and brain taken from a Sprague-
Dawley rat. All three antibodies could detect a specific band
corresponding to aDG (Fig. 3A). The molecular weight of the
aDG detected was variable based on the tissue type (skeletal
muscle, heart, or brain), as aDG is known to exist at different sizes
in different tissues due to variable glycosylation status [28].
Detection of glycosylated aDG using mouse monoclonal IIH6
revealed bands of corresponding sizes, confirming the detection of
aDG by aDGct antibody supernatants. Use of these antibodies to
detect aDG on cryosectioned rat tibialis anterior muscle tissue
showed positive immunofluorescent staining at the sarcolemma, as
expected (Fig. 3B).
Detection of aDG in a pig model of Becker muscular
dystrophy
After determining that aDGct antibodies 5–2, 29–5, and 49–3
can detect aDG in both its normal and abnormally glycosylated
states in rodent tissues, the antibodies were tested for the ability to
detect aDG in an emerging disease model species, when
abundance of the protein is significantly reduced. Becker muscular
dystrophy (BMD) is a condition in which disruption in the
dystrophin gene and the subsequent decrease in cytoplasmic
dystrophin cause a- and bDG accumulation to be reduced at the
sarcolemma. IIH6 detection of glycosylated aDG on BMD-
affected pig skeletal muscle revealed a significantly fainter band of
equivalent molecular weight compared to the control pig skeletal
muscle, therefore showing a reduction in the amount of aDG
present, but not its size (Fig. 4A, B, IIH6). Interestingly, aDG
detection appeared to arise from a doublet of bands at 170 and
150 kDa in both healthy and BMD-affected samples. When rabbit
aDGct antibody supernatants were used, aDG core protein
expression was also reduced in BMD-affected samples compared
to healthy controls (Fig. 4A, B). aDGct supernatant 5–2 had the
weakest detection of aDG, with bands in most but not all the
control samples and no detection of aDG in the BMD-affected
muscle. Of the rabbit monoclonal antibodies, supernatant 5–2 also
detected the highest MW aDG species at 170 kDa (Fig. 4A). An
additional 130 kDa band was detected in some samples by 5–2,
however this band is expected to be non-specific background as its
intensities were not significantly different between BMD-affected
and healthy samples. Both 29–5 and 45–3 aDGct antibodies
reproducibly detected higher expression of aDG in the control
compared to the BMD-affected samples, although they detected
the smaller molecular weight population of glycosylated aDG at
approximately 150 kDa, suggesting that the antigen epitopes of
29–5 and 45–3 may be more similar than that of aDGct antibody
5–2 (Fig. 4A, B).
To further address the molecular weight of aDG species and
potential background detection in pig, skeletal muscle from both
normal healthy and BMD-affected pigs was solubilized and
enriched by WGA purification. As shown in Fig. 4C, the previous
150 and 170 kDa doublet pattern was replaced by a broad aDG
band that was similar to detection of glycosylated aDG by IIH6.
Additional bands under 100 kDa were still present at varying
intensities that were not correlated with the expression level of the
normal aDG protein.
Rabbit media supernatant 45–3 was also tested on pig muscle
cryosections because it had the most robust detection on mouse
dystrophic muscle sections and on preliminary immunoblot testing
with pig lysates. The sarcolemma was labeled with an intensity
equivalent to labeling with IIH6 on control pig skeletal muscle
sections. Staining of BMD-affected pig sections was again
equivalent to that of IIH6, with reductions in sarcolemma staining
and patchy fiber labeling as expected in the BMD-affected model
(Fig. 3D). A decrease in aDG staining (both core and glycosylated)
in BMD-affected muscle sections compared to healthy controls
was confirmed by pixel quantification (Fig. 3E).
Detection of aDG in other species
aDGct monoclonal antibodies were tested on rabbit aDG by
Western blot. No major bands were detected in HEK-293T lysates
expressing the recombinant full-length rabbit aDG fusion protein
DGFc5 (data not shown). The lack of specificity for rabbit protein
may be due to the generation of the hybridomas from a rabbit host
(although rabbit aDG has 163/168 amino acid identity with the
mouse antigen) or steric hindrance by the C-terminal Fc fusion
protein.
In addition, both Western blot and immunofluorescence were
performed on human samples. For human skeletal muscle and
human heart protein lysates, media supernatants of aDGct
antibodies 5–2, 29–5, and 45–3 did not detect endogenous human
aDG, even though robust aDG signal was detected in both tissues
using the glycosylated aDG antibody IIH6 (Fig. S1A). Similar
experiments were performed using WGA to enrich aDG (and
other glycosylated proteins) from human skeletal muscle and heart
(Fig. S1B). While faint bands were detected in WGA void samples
by media supernatants of 29–5 and 45–3, there was no detection
of endogenous aDG in the WGA elution, which was strongly
labelled by IIH6. Detection of aDG from mouse skeletal muscle
lysate confirmed that both 29–5 and 45–3 antibodies were active.
Antibody 5–2 was not sensitive enough to detect any bands, even
mouse skeletal muscle lysate, on the stripped human blots.
The dilute media supernatant antibody fractions used may
simply lack the sensitivity to detect human aDG protein.
Therefore, serum-free fractions, which contain much higher
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concentrations of antibody, were also tested (Fig. S1C). At a
dilution of 1:100, serum-free aDGct antibodies 5–2, 29–5, and 45–
3 clearly labelled mouse protein but did not detect WGA-enriched
human aDG, even though IIH6 showed very strong detection of
the glycosylated protein. The serum-free fraction of 45–3, the
strongest antibody in these experiments, was further tested at a
dilution of 1:25, but no major human bands were labelled.
Lastly, aDGct monoclonal 5–2, 29–5, and 45–3 media
supernatants (at 1:3 dilution) and serum-free fractions (at dilutions
of 1:20 and 1:10 for all antibodies, and 1:5, 45–3 only) were tested
on formalin fixed paraffin embedded human diaphragm sections
using indirect immunofluorescence (Fig. S1D and data not
shown). The muscle fiber membranes were clearly labelled by
glycosylation-specific antibody IIH6. However, 5–2, 29–5, and
45–3 treated sections showed only occasional puncta and rare
short regions of muscle membrane staining that were similar to
background staining with no primary antibody. Consequently,
antibodies 5–2, 29–5, and 45–3 appear to have low or no
sensitivity for human aDG.
Discussion
To date, research into the role of dystroglycan glycosylation in
various pathological processes has been restricted by the limited
supply of suitable reagents for detection of abnormally glycosylated
aDG. The standard reagent for aDG detection, IIH6, cannot
distinguish between an absence of aDG protein versus a failure in
functional glycosylation of aDG due to its requirement of the
functional O-mannose glycan for aDG detection. The most
commonly used reagents for non-glycan-dependent aDG detec-
tion have been polyclonal antisera Gt20adg, Sheep 5, and sheep
anti-aDG [2], [29]. Such reagents, however, are limited in supply
and are not commercially available. Pavoni et al. generated a
mouse monoclonal antibody against a highly conserved sequence
in the aDG C-terminus (Fig. 4, amino acids 547–564); however
the antibody was unable to detect fully glycosylated aDG, limiting
its application [30]. While detection of bDG is often used as a
proxy for dystroglycan protein expression, it is not ideal since aDG
can be shed from the dystroglycan complex, particularly in cell
culture conditions [31]. The monoclonal antibodies generated in
this study provide a much improved alternative, as they can easily
be generated from hybridoma subclones, they are more specific in
epitope recognition than polyclonal sera, and they can directly
detect aDG.
Tests with immunoblotting and immunofluorescence show that
rabbit aDGct supernatants 5–2, 29–5 and 45–3 are relatively
similar in the ability to detect aDG core protein in skeletal muscle,
heart, and brain of mouse and rat, although in side-by-side
experiments signal from 45–3 tends to be a little stronger.
Detection in pig tissue had more variability, with 5–2 showing
more limited ability to label aDG than 29–5 and 45–3. While
glycosylated aDG typically distributes as a broad band, indicating
a mixture of variably glycosylated subspecies, it was notable that in
pig skeletal muscle lysates, aDG distributed into two more distinct
subspecies in most samples detected by glycosylated aDG antibody
IIH6. Supernatant 5–2 showed specificity for the higher 170 kDa
pig lysate aDG. In contrast, 29–5 and 45–3 only detected the 150
kDa aDG isoform of the lysate pair, but also exposed some
additional lower molecular weight bands. The lower molecular
weight bands are expected to be nonspecific background rather
than aDG degradation products because they did not colabel with
IIH6 and there was no apparent pattern of intensities between
BMD-affected versus healthy samples.
To further address the multiple aDG species versus potential
background bands in pig lysate samples, WGA-enriched samples
were also tested. In WGA elution fractions, the distinct aDG
doublet found in some lysate samples was no longer apparent. Loss
of the aDG doublet could be a technical artifact of two different
SDS-PAGE systems (mini-gel vs. large gel). Alternately, uniden-
tified proteins that do not bind WGA could be co-migrating with
aDG in lysate, but not WGA elution samples, shifting its
distribution. Core aDG monoclonal antibodies showed detection
of a broad 145 kDa –190 kDa band, similar to glycosylation-
specific IIH6. Additional lower molecular weight bands were also
detected by the aDGct antibodies, as in the lysate samples. As the
intensity of these bands was not highly correlated, positively or
negatively, with intensity of the known aDG band or the sample
group (normal vs. affected), it is unlikely that they are aDG
protein. However, the possibility of lower molecular weight aDG
species with reduced glycosylation or proteolytic cleavage cannot
be ruled out.
Though good detection of aDG was seen among different
species – the antibodies were all effective in mouse, rat, and pig –
detection of human or recombinant Fc-tagged rabbit aDG was not
observed. It is possible that the small number of amino acid
differences among species affect the epitopes recognized by 5–2,
29–5 and 45–2. However, comparison of species with aDGct
monoclonal antibody detection (mouse, rat, pig) versus species
lacking detection in these experiments (rabbit fusion protein,
human) only finds one of the 197 amino acid residues of the C-
terminal mouse antigen that specifically segregates according to
antibody sensitivity (Fig. 5; CLUSTAL 2.1 alignment of Uniprot
No: mouse Q62165 a.a. 484–651; rat F1M8K0 a.a. 484–651; pig
I3LD20 a.a. 469–635; Human Q14118 a.a. 486–653; rabbit
Q28685 a.a. 486–653). Asn524 is shared by mouse, rat and pig,
while human and rabbit contain His and Lys residues at the
equivalent positions. Therefore, this position or some combination
of other non-shared changes might underlie the loss of aDGct
antibody sensitivity for detection of human and rabbit species.
Lack of detection of rabbit aDG may be due to steric hindrance of
the C-terminus by the Fc fusion tag. If that is true, then other
residues may contribute to the lack of sensitivity for human aDG.
In the antigen region, there are a total of 9 non-identical residues
in human versus mouse aDG (Fig. 5; mouse residues 524, 595,
601, 609, 610, 611, 616, 618, and 652). In addition to the
Asn524.His difference described above, Pro616.Leu and
Val618.Leu are the only other changes in the human sequence
that are not shared with the pig. Loss of conformational rigidity
with Pro616, in particular, could be important for the antibody
epitope.
Dystroglycanopathies result in a loss of aDG functional
glycosylation, therefore glycosylation-specific antibody IIH6 can
only detect the absence of glycosylated aDG, and not its mutant
abnormally glycosylated form. By detecting a core epitope of
aDG, these aDGct antibodies fill an important role in that they
can provide specific detection of normal and glycosylation-
deficient aDG species as demonstrated in fukutin-deficient mice.
As the antibodies are monoclonal and produced in rabbit, they are
ideally suited for use in mouse dystroglycanopathy models,
although other non-Fktn dystroglycanopathy mice will need to be
tested to validate the antibodies for a wider array of glycosylation-
deficient aDG variants. The three aDGct monoclonal antibodies
reported here, 5–2, 29–5, and 45–3, may also have some
variability in sensitivity for highly glycosylated aDG, as seen in
pig skeletal muscle lysates. It is expected that these new core aDG
antibodies will be useful in furthering the understanding of
dystroglycanopathies and other dystroglycan-linked pathologies.
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Supporting Information
Figure S1 aDG detection in human tissue samples. A)
Human skeletal muscle (SkM) and heart (H) lysates were analyzed
with IIH6 glycosylation-specific aDG antibody and aDG core
monoclonal antibody media supernatants 5–2, 29–5, and 45–3 by
Western blot. All molecular weight standards are indicated in kDa.
B) WGA purification of human SkM and H lysates were
conducted. The elution and void fractions from each were
immunoblotted with IIH6, and media supernatant fractions of
5–2, 29–5 and 45–3. Skeletal muscle lysate from a normal mouse
was included for comparison (Mse SkM). C) WGA purification of
human SkM: elution and void fractions, plus normal mouse SkM
lysate, were analyzed by immunoblotting with IIH6 and serum-
free fractions of monoclonal antibodies 5–2, 29–5, and 45–3. D)
Immunofluorescence of formalin fixed, paraffin embedded
sections from a normal human diaphragm with IIH6 and
serum-free fractions of 5–2, 29–5, and 45–3. Controls with
secondary antibody only are shown (2nd ctrl). 20X objective,
50 mm scale bar.
(TIF)
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